Vaxart, Inc. is anchored in developing oral recombinant protein vaccines, uniquely positioning itself within the vaccine technology niche. The latest 10-Q reveals a significant revenue increase driven by government contracts, facilitating ongoing R&D investment amid operating losses. A November 2025 licensing and equity transaction with Dynavax injects $30 million of capital, extending the cash runway into mid-2027 and alleviating prior going-concern doubts. The company’s business model relies on partnerships, government funding, and licensing fees, targeting infectious diseases via oral vaccines that may offer convenience and compliance advantages. While clinical and regulatory uncertainties persist, Vaxart’s proprietary platform and collaboration network underpin a differentiated competitive stance. Monitoring clinical trial milestones and regulatory interactions will be critical for assessing future inflection points.